StockData
Actuate Therapeutics, Inc. logo

Actuate Therapeutics, Inc. (ACTU) stock

ACTUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 0/30
$0.25−0.02 (-6.12%)

Close on Nov 17, 2026Market cap $6.04MP/E –Yield –

Actuate Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Actuate Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $8.57M, down 27.6% year over year. For fiscal 2025 it was $10.29M, down 44.9% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$10.29M-44.9%
FY2024Dec 31, 2024$18.68M-14.0%
FY2023Dec 31, 2023$21.71M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.81M-16.8%
Q2 FY2026Jun 30, 2026$2.07M-25.2%
Q1 FY2026Mar 31, 2026$2.57M-20.3%
Q4 FY2025Dec 31, 2025$2.13M-42.2%
Q3 FY2025Sep 30, 2025$2.18M-42.0%
Q2 FY2025Jun 30, 2025$2.76M-36.8%
Q1 FY2025Mar 31, 2025$3.22M-53.1%
Q4 FY2024Dec 31, 2024$3.69M-44.5%
Q3 FY2024Sep 30, 2024$3.76M-34.8%
Q2 FY2024Jun 30, 2024$4.37M-8.5%
Q1 FY2024Mar 31, 2024$6.86M–
Q4 FY2023Dec 31, 2023$6.65M–
Q3 FY2023Sep 30, 2023$5.76M–
Q2 FY2023Jun 30, 2023$4.78M–

More Actuate Therapeutics figures

See a number that looks wrong?